UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
Form
6-K
Report
of Foreign Private Issuer
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
For the
month of September, 2010
Commission
File Number: 000-51310
|
XTL
Biopharmaceuticals Ltd.
|
|
(Translation
of registrant’s name into English)
|
|
85
Medinat Hayehudim St., Herzliya Pituach, PO Box 4033,
Herzliya
46140, Israel.
|
|
(Address
of principal executive
offices)
|
Indicate
by check mark whether the registrant files or will file annual reports under
cover Form 20-F or Form 40-F.
Form
20-F x Form
40-F o
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): ____
Indicate
by check mark whether by furnishing the information contained in this Form, the
registrant is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
Yes o No x
If “Yes”
is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82- N/A
Incorporation
by Reference: This Form
6-K of XTL Biopharmaceuticals Ltd. dated September 28, 2010 is hereby
incorporated by reference into the registration statements on Form F-3 (File No.
333-141529, File No. 333-147024 and File No. 333-153055) filed by XTL
Biopharmaceuticals Ltd. with the Securities and Exchange Commission on March 23,
2007 , October 30, 2007 and August 15, 2008, respectively, and the registration
statements on Form S-8 (File No. 333-148085, File No. 333-148754 and File No.
333-154795) filed by XTL Biopharmaceuticals Ltd. with the Securities and
Exchange Commission on December 14, 2007, January 18, 2008, and October 28,
2008, respectively.
XTL
Biopharmaceuticals Announces
Canadian
Patent Office Approval
Attached hereto
is an English translation (from Hebrew) of an announcement, as submitted on Tel
Aviv Stock Exchange, that the Canadian Patent Office has approved a patent
granting XTL Biopharmaceuticals Ltd. the exclusive right to use Erythropoietin
for treating terminal patients suffering from multiple myeloma.
- 2
-
XTL Biopharmaceuticals,
Ltd.
(the
“Company”)
September
26, 2010
|
The
Tel Aviv Stock Exchange Ltd.
Via
Magna
|
The
Securities Authority
Via
Magna
|
Dear
Sirs,
Re: Immediate
Report
The
Company hereby announces that on Sunday, September 19th, 2010,
it received notice from its patent attorneys that the Canadian Patent Office had
approved a patent granting the Company the exclusive right to use the
Erythropoietin drug ("EPO") for treating terminal patients suffering from
multiple myeloma (a type of blood cancer) until 2019. This patent
represents an important addition to our patent portfolio and to the prospect of
awarding the Company exclusivity on EPO for multiple myeloma in Canada, which
has a population of 33 million people. Furthermore, according to the Myeloma
Canada Organization, 1.9% of cancer mortality cases stem from multiple
myeloma.
Approval
of the patent in Canada merges with the Company's registered patents, granting
it the exclusive use of EPO for treating terminal patients suffering from
multiple myeloma in the following countries: USA, Europe, Israel, Hong Kong and
Japan. This approval is the last on the Company's list of patent
applications relating to EPO.
It should
be noted that the Company has obtained the approval of all the patent offices in
the relevant countries where patent registration applications had been
filed.
- 3
-
As
previously mentioned, the Company is currently engaged, inter alia, in making
preparations for commencing the Phase 2 clinical trial in cancer
patients. Multiple myeloma is a terminal blood cell
cancer. Alternative medications available to patients suffering from
this disease that may prolong and improve the quality of life are
limited.
The
Company estimates that the patents in its possession
will provide legal protection for the exclusive use of EPO drug for
the treatment of cancer patients suffering from multiple myeloma.
Respectfully,
XTL
Biopharmaceuticals, Ltd.
- 4
-
Contact:
Investor
Relations, XTL Biopharmaceuticals Ltd.
Tel:
+972 9 955 7080, Email: ir@xtlbio.com
Cautionary
Statement
Some of
the statements included in this Form 6-K may be forward-looking statements that
involve a number of risks and uncertainties. For those statements, we claim the
protection of the safe harbor for forward-looking statements contained in the
Private Securities Litigation Reform Act of 1995.
- 5
-
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
| XTL BIOPHARMACEUTICALS LTD. | |||
|
Date:
September 28, 2010
|
By:
|
/s/ David Grossman | |
| David Grossman | |||
| Chief Executive Officer | |||
- 6
-